A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy

Biomaterials

Volumn 33, Issue 34, 2012, Pages 8893-8905

  Ding, Yang ^a   Wang, Wei ^a   Feng, Meiqing ^b   Wang, Yu ^c   Zhou, Jianping ^a   Ding, Xuefang ^a   Zhou, Xin ^a   Liu, Congyan ^a   Wang, Ruoning ^a   Zhang, Qiang ^d  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Apolipoprotein A I; Pokemon; Reconstituted high density lipoprotein; Targeted cholesterol conjugated siRNA delivery; Tumor gene therapy

Indexed keywords

APOLIPOPROTEIN A-I; HIGH DENSITY LIPOPROTEIN; POKEMON; SIRNA DELIVERY; TUMOR GENE THERAPY;

BIOMIMETICS; CELL CULTURE; CELL DEATH; CHOLESTEROL; GENETIC ENGINEERING; INFRARED DEVICES; MOLECULAR BIOLOGY; NANOPARTICLES; PROTEINS; RNA; TUMORS;

GENE THERAPY;

CHOLESTEROL CONJUGATED SMALL INTERFERING RNA; HIGH DENSITY LIPOPROTEIN; NANOCARRIER; PROTEIN BCL 2; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG STABILITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR STABILITY; NONVIRAL GENE THERAPY; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SUSTAINED DRUG RELEASE; WESTERN BLOTTING;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHOLESTEROL; CHOLESTEROL, HDL; DNA-BINDING PROTEINS; GENETIC THERAPY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

MUS MUSCULUS;

EID: 84866866686     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.08.057     Document Type: Article

References (43)

1. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007, 6:443-453.
2. Iorns E., Lord C.J., Turner N., Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007, 6:556-568.
3. Kim D., Rossi J. RNAi mechanisms and applications. Biotechniques 2008, 44:613-616.
4. Zhang N., Tan C., Cai P., Zhang P., Zhao Y., Jiang Y. RNA interference in mammalian cells by siRNAs modified with morpholino nucleoside analogues. Bioorg Med Chem 2009, 17:2441-2446.
5. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007, 25:1149-1157.
6. Fattal E., Bochot A. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers. Int J Pharm 2008, 364:237-248.
7. Chiu Y.L., Ali A., Chu C.Y., Cao H., Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004, 11:1165-1175.
8. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005, 23:709-717.
9. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
10. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23:1002-1007.
11. Lorenz C., Hadwiger P., John M., Vornlocher H.P., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004, 14:4975-4977.
12. Sioud M., Sorensen D.R. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003, 312:1220-1225.
13. Meade B.R., Dowdy S.F. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 2007, 59:134-140.
14. Rigotti A., Miettinen H.E., Krieger M. The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev 2003, 24:357-387.
15. Rensen P.C., de Vrueh R.L., Kuiper J., Bijsterbosch M.K., Biessen E.A., van Berkel T.J. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001, 47:251-276.
16. Connelly M.A., Williams D.L. SR-BI and HDL cholesteryl ester metabolism. Endocr Res 2004, 30:697-703.
17. Connelly M.A., Williams D.L. Scavenger receptor BI: a scavenger receptor with a mission to transport high density lipoprotein lipids. Curr Opin Lipidol 2004, 15:287-295.
18. Zannis V.I., Chroni A., Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med (Berl) 2006, 84:276-294.
19. Pussinen P.J., Lindner H., Glatter O., Reicher H., Kostner G.M., Wintersperger A., et al. Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells. Biochim Biophys Acta 2000, 1485:129-144.
20. Lacko A.G., Nair M., Paranjape S., Johnso S., McConathy W.J. High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res 2002, 22:2045-2049.
21. Lou B., Liao X.L., Wu M.P., Cheng P.F., Yin C.Y., Fei Z. High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol 2005, 11:954-959.
22. McConathy W.J., Nair M.P., Paranjape S., Mooberry L., Lacko A.G. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008, 19:183-188.
23. Maeda T., Hobbs R.M., Merghoub T., Guernah I., Zelent A., Cordon-Cardo C., et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 2005, 433:278-285.
24. Maeda T., Hobbs R.M., Pandolfi P.P. The transcription factor Pokemon: a new key player in cancer pathogenesis. Cancer Res 2005, 65:8575-8578.
25. Agrawal A., Yang J., Murphy R.F., Agrawal D.K. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp Mol Pathol 2006, 81:115-122.
26. Apostolopoulou K., Pateras I.S., Evangelou K., Tsantoulis P.K., Liontos M., Kittas C., et al. Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer. J Pathol 2007, 213:294-302.
27. Cui J., Meng X., Gao X., Tan G. Curcumin decreases the expression of Pokemon by suppressing the binding activity of the Sp1 protein in human lung cancer cells. Mol Biol Rep 2010, 37:1627-1632.
28. Jeon B.N., Yoo J.Y., Choi W.I., Lee C.E., Yoon H.G., Hur M.W. Proto-oncogene FBI-1 (Pokemon/ZBTB7A) represses transcription of the tumor suppressor Rb gene via binding competition with Sp1 and recruitment of co-repressors. J Biol Chem 2008, 283:33199-33210.
29. Zhao Z.H., Wang S.F., Yu L., Wang J., Chang H., Yan W.L., et al. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Lung Cancer 2008, 62:113-119.
30. Choi W.I., Jeon B.N., Yun C.O., Kim P.H., Kim S.E., Choi K.Y., et al. Proto-oncogene FBI-1 represses transcription of p21CIP1 by inhibition of transcription activation by p53 and Sp1. J Biol Chem 2009, 284:12633-12644.
31. Zhang W.L., Xiao Y., Liu J.P., Wu Z.M., Gu X., Xu Y.M., et al. Structure and remodeling behavior of drug-loaded high density lipoproteins and their atherosclerotic plaque targeting mechanism in foam cell model. Int J Pharm 2011, 419:314-321.
32. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004, 32:e149.
33. Baker M. RNA interference: Homing in on delivery. Nature 2010, 464:1225-1228.
34. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005, 12:461-466.
35. Li W., Szoka F.C. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007, 24:438-449.
36. Sriamornsak P., Thirawong N., Nunthanid J., Puttipipatkhachorn S., Thongborisute J., Takeuchi H. Atomic force microscopy imaging of novel self-assembling pectin-liposome nanocomplexes. Carbohydr Polym 2008, 71:324-329.
37. Collet X., Tall A.R., Serajuddin H., Guendouzi K., Royer L., Oliveira H., et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 1999, 40:1185-1193.
38. Song J.J., Smith S.K., Hannon G.J., Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004, 305:1434-1437.
39. Ng K.K., Lovell J.F., Zheng G. Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 2011, 44:1105-1113.
40. Zhong Z., Feijen J., Lok M.C., Hennink W.E., Christensen L.V., Yockman J.W., et al. Low molecular weight linear polyethylenimine-b-poly(ethylene glycol)-b-polyethylenimine triblock copolymers: synthesis, characterization, and in vitro gene transfer properties. Biomacromolecules 2005, 6:3440-3448.
41. Feng M., Cai Q., Huang H., Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 2008, 68:688-693.
42. Feng M., Cai Q., Shi X., Huang H., Zhou P., Guo X. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J Drug Target 2008, 16:502-508.
43. Mooberry L.K., Nair M., Paranjape S., McConathy W.J., Lacko A.G. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 2010, 18:53-58.